Saphris Approved for Pediatric Bipolar Disorder—What Do the Data Show?
The Carlat Child Psychiatry Report, Volume 6, Number 3, April 2015
https://www.thecarlatreport.com/newsletter-issue/ccprv6n3/
Issue Links: Learning Objectives | Editorial Information
Topics: Antipsychotics | Bipolar Disorder | Child Psychiatry | News of Note
In March 2015, the US Food and Drug Administration (FDA) approved Actavis’ asenapine (Saphris) for the acute treatment of manic or mixed episodes associated with bipolar disorder in kids between 10 and 17 years.
You can't view details of this content, please login or buy subscription here